This section introduces the challenges 3D bioprinting poses to the existing legal regime across bioethics, safety, regenerative medicine, and tissue engineering. We briefly review the 3D bioprinting technology and look into the relevant regulatory instruments for the pre-printing, printing, and post-printing stages. Special attention is paid to the applications of the EU Advanced Therapy
I. Introduction
With the technological breakthrough in additive manufacturing (AM, aka, 3 Dimensional printing, 3D printing), 3D bioprinting technologies have emerged as an efficient tool for tissue engineering and regenerative medicine by adopting computer-aided manufacturing (CAM) into healthcare delivery. The disruptive nature of the 3D bioprinting technologies not only weaves a dream of 'printed-organ-on-demand', but also challenges the traditional regulatory framework.
There is currently not a sui generis regulatory regime governing the whole bioprinting process but piecemeal legislations are relevant in relation to tissue engineering and regenerative medicine. Regenerative medicine using cell or tissue engineering is considered advanced therapy in the European Commission (EC) Regulation on Advanced Therapy Medicinal Products (ATMP). 1 *Phoebe Li is Senior Lecturer in Law at the University of Sussex (email: Phoebe.Li@sussex.ac.uk). Alex Faulkner is Professor in Sociology of Biomedicine & Healthcare Policy, University of Sussex. 'This article is based on the project 'A feasibility study of mass customisation governance: regulation, liability, and
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The principles developed in the ATMP Regulation are applicable to 3D bioprinting. Relevant legal instruments include the ATMP Regulation, the EC Tissues and Cells Directive, 2 pharmaceutical regulations, 3 and the new Medical Device Regulation, 4 all being applicable at different stages of production.
The product development of 3D bioprinting technologies involves 'Re-distributed Manufacturing (RDM)', which means that the manufacturing process is taking place at several technical stages at multiple sites rather than at a single central manufacturing plant. 5 Various factors will affect the quality of materials and products. Quality assurance and testing is required at every stage of manufacturing before moving onto the next site for further processing. Hence, this section will analyse associated issues arising from each step in the manufacturing process: pre-printing, printing, post-processing, and testing and characterisation.
intellectual property of re-distributed manufacturing in 3D printing', funded by the UK EPSRC (Engineering and Physical Sciences Research Council, Institute for Manufacturing at Cambridge University, EP/M017656/1). All data created during this research are openly available from the University of Cambridge data archive at: https://capturingthevalue.wordpress.com/3dp-rdm-reports/. 
II. Bioprinting technology
3D bioprinting technology is primarily driven by three factors: the quality of bioprinters and source materials, computer-aided design (CAD) software, and advances in the science and application of regenerative medicine. Regenerative medicine means using the self-healing processes of the human body by therapeutic products of tissue and cell engineering, which is the process of generating repair tissues and organs (bioartificial tissues) using cells from an individual patient (to create tissues outside the body and then implant them). The advantage of using a patient's autologous cells rather than donor biomaterial is that it decreases tissue rejection.
The following are the steps involved in using a bioprinter with autologous cells: collect and grow stem cells or mesenchymal (multipotent) cells from patient biopsies; make 'bio-ink' from enough cells and load into the cartridge; use the bio-ink and a hydrogel-carrying medium to print tissues guided by software and a bioprinter; the printed tissues are left to mature for several weeks. 6 After maturation, the printed tissues can be used in medical research, new drug testing, or as a transplant material. 3D bioprinted organs are anticipated to relieve the shortage of transplantable organs thus preventing the complications of sources and commercialisation of human organs. Meanwhile less complex clinical applications such as bioactive nasal prostheses are being developed. It is expected that in the near future such a bioprinter could be an essential tool for in-vivo printing in the hospital operating theatre.
III. Bioprinting regulations
Bioprinting is a subcategory of 3D printing though the same regulation rationale cannot be applied due to the inherently different 
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policy considerations for protecting human health and safety. These range from the fundamental philosophical and bioethical issues to practical risk, biosafety and security concerns. 3D bioprinting presents the recurrent risks and challenges arising from implantable medical devices, cell therapy, stem cell therapy, and organ transplantation. Safety issues include sources of biomaterials, unhealthy donors, implant efficacy, and post-transplant infections.
Current regulatory regimes on cell therapy and stem cell research lack clarity when considering their application to bioprinting regulation. The legal uncertainties of bioprinting are further compounded by the multiple actors involved in the supply and production chain. Specifically, the adoption of computer-aided manufacturing (CAM) of bioprinting (through which computer-aided design (CAD) software is used to customise the product to an individual patient and to trigger the bioprinting process) further complicates the legal landscape.
Source of materials
Researchers have long been culturing and reproducing cells in laboratories, including skin tissues, blood vessels, and other cells from various organs. There is a wide range of materials which could be used in bioprinting. In addition to cells and collagen, autologous stem cells are an attractive option for use as bio-ink for printing different organs and tissues as they may adapt easily to host tissues.
The 3D bioprinted product using bio-ink developed from autologous cells would reduce the patient's rejection rate, though in certain circumstances it is also possible to use allogeneic cells for fabrication. Cells and tissues are first acquired from a patient or a donor before the initial processing of cell releasing from tissue matrix, cell isolation/enrichment, cell culture, harvest, and encapsulation of cells in hydrogel. 7 In order to ensure the quality and safety of cell and tissue material, the early stage of donation, procurement, Medicines: Convention on Human Rights and Biomedicine. It is recognised that the same regulatory principles for other types of pharmaceutical medicinal products should be applicable to ATMP where they are comparable, and that specific technical requirements with regard to quality and clinical data to ensure quality, safety and efficacy, may also be required. The central Committee for Advanced Therapies (CAT), which implements the ATMP Regulation by assessing newly notified products, acts as an advisory body to the over-arching European Medicines Agency. The ATMP Regulation stresses that the procurement of human cells or tissues used in ATMP should be derived from voluntary and unpaid donation, and that the anonymity of, and solidarity between, donor and recipient should be respected.
Bioprinting triggered by Computer-Aided Manufacturing
The printing process is triggered by the instructions generated by computer-aided design (CAD) or computer-aided manufacturing (CAM) systems. The customised CAD file is generated by 3D scanning and image segmentation. The medical use of 3D printers involves a digital file generated from 3D scanning of a human body part, and reprinting at the wound site for repair. In medical use, researchers could use the digital data acquired from Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) scans to make a 3D design model of an organ or other tissue. It is then used in the software designing process in order to modify the design for customisation. The next step is to convert the design or data into a STL file. The STL file is then imported into the printer software package to set up the machine for printing. It is then to be reviewed and verified by a surgeon to make possible patientspecific tailoring decisions before triggering the CAM process.
Mass digitisation and dissemination of STL files poses risks to the regulatory framework of consumer safety, product liability (quality control), and data protection, confidentiality, and safety. A major issue is that the design involves multiple translation and compilation steps between different software applications, each having different error sensitivities, hence errors in customisation settings are likely to occur. The current computer-aided process planning still relies on human expertise and manual interaction so products are used via this 'hospital exemption' (a similar though not identical scheme is called 'Specials' in the UK 23 ). However, some aspects of its application remain unclear especially the question of whether bioprinted products, which combine some standardised processes (e.g. in the software and machinery) with unique individual cells, will be deemed to be 'routine' or 'nonroutine' manufacturing -an important factor for determining the regulatory measures and data requirements.
The production of ATMPs should follow the principles of good manufacturing practice, and good clinical practice when conducting clinical trials. If producers seek to market a product, clinical trials on ATMPs are required for central EMA market authorisation. It is also noteworthy that a 'combined' ATMP comprised of both medical device and viable cells or tissues, will require pre-market approval from the EMA, which involves assessment for both the medical device part and the medicinal product part. After the bioprinting process, traceability of the patient and the ATMP is required to monitor the safety of ATMP. It is required that the holder of marketing authorisation keeps the relevant data for a minimum of 30 year after the expiry date of the product for follow-up of efficacy and risk management post-authorisation. 24 This places a significant onus on producers, hospitals and even physicians in data collection and storage, depending on where the liability is determined to lie.
IV. Future trends
The emergence of 3D bioprinting presents a potentially useful tool for tissue engineering and regenerative medicine that is attracting a great deal of development effort, yet the novel production methods and the products themselves challenge the existing boundaries in the healthcare regulatory sphere. It remains to be seen whether the 'mass customisation' that bioprinting allows will find the EU ATMP Regulation and the new Medical Device Regulation sufficient for bioprinting regulation, or how the existing laws 23 "Supply unlicensed medicinal products in the UK (Specials)", available at: https://www.gov.uk/government/publications/supply-unlicensed-medicinalproducts-specials (last accessed 28 February 2017) 24 Article 15(4) ATMP.
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might require adaptation to meet the challenges of bioprinting. It is expected that public debates will need to take place in the near future on the development pathway of the technology, and the regulatory status of its processes and products. Policymakers will also need to make an informed decision on whether to have bioprinting products and services covered by national or private health insurance.
